
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc has demonstrated significant financial growth with its Q3 revenue reaching $18,942, marking a 31% year-over-year increase, primarily attributed to an 89% rise in Nociscan report volumes. The company is making notable strides in the market, evidenced by substantial commercial agreements with reputable healthcare providers such as Scripps Health and affiliates of RadNet, which enhances its revenue-generating capabilities through increased adoption of the Nociscan platform. The ongoing CLARITY trial and favorable coverage developments in the UK are expected to further drive momentum, indicating a strong potential for continued growth in both revenues and market presence.
Bears say
Aclarion Inc faces significant challenges that justify a negative outlook on its stock, primarily due to slower-than-expected market traction with both surgeons and payers, which could hinder revenue growth from its sole product, the Nociscan platform. The company is also experiencing rising marketing and administrative expenses, leading to downward adjustments in its fiscal year 2025 earnings per share (EPS) estimates, which reflect a continuous increase in operating costs. Additionally, notable risks such as balance sheet/liquidity concerns, regulatory approval hurdles, and competitive pressures further complicate Aclarion's path to sustainable profitability.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares